comparemela.com

Latest Breaking News On - Aquilo capital management - Page 1 : comparemela.com

Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update

Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United-kingdom
Australia
Michael-amoroso
Azercabtagene-zapreleucel
Gene-insertion-program
Elimination-program
Development-expenses
Viral-elimination-program
Aquilo-capital-management
University-of-pennsylvania-gene-therapy-program
Drug-administration
Nasdaq

Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants

Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

New-york
United-states
Exchange-commission
Precision-biosciences-inc
Aquilo-capital-management
Equity-syndicate-department
Nasdaq
Guggenheim-securities
Precision-biosciences
Perceptive-advisors
Janus-henderson-investors

Spero Therapeutics, Inc. (NASDAQ:SPRO) Expected to Post Quarterly Sales of $2.65 Million

Brokerages expect Spero Therapeutics, Inc. (NASDAQ:SPRO – Get Rating) to report sales of $2.65 million for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Spero Therapeutics’ earnings. The lowest sales estimate is $2.30 million and the highest is $3.00 million. Spero Therapeutics posted sales of $5.15 million during the […]

United-states
Berenberg-bank
Goldman-sachs-group-inc
Zacks-investment-research
Spero-therapeutics-company-profile-get-rating
Blackrock-inc
Nasdaq
Marshall-wace
Wells-fargo-company
Cantor-fitzgerald
Spero-therapeutics-inc

Spero Therapeutics, Inc. (NASDAQ:SPRO) Sees Large Drop in Short Interest

Spero Therapeutics, Inc. (NASDAQ:SPRO – Get Rating) was the target of a large decline in short interest during the month of May. As of May 15th, there was short interest totalling 1,650,000 shares, a decline of 55.3% from the April 30th total of 3,690,000 shares. Based on an average daily volume of 634,900 shares, the […]

Blackrock
Nova-scotia
Canada
United-states
Securities-exchange-commission
Berenberg-bank
Zacks-investment-research
Blackrock-inc
Nasdaq
Patriot-financial-group-insurance-agency
Granahan-investment-management-inc

-$0.77 EPS Expected for Spero Therapeutics, Inc. (NASDAQ:SPRO) This Quarter

Wall Street analysts expect Spero Therapeutics, Inc. (NASDAQ:SPRO – Get Rating) to announce earnings of ($0.77) per share for the current quarter, according to Zacks. Two analysts have issued estimates for Spero Therapeutics’ earnings. The lowest EPS estimate is ($0.90) and the highest is ($0.56). Spero Therapeutics posted earnings per share of ($0.63) during the […]

United-states
Allspring-global-investments-holdings
Securities-exchange-commission
Berenberg-bank
Zacks-investment-research
Nasdaq
Marshall-wace
Patriot-financial-group-insurance-agency
Cantor-fitzgerald
Spero-therapeutics-inc
Aquilo-capital-management-llc

vimarsana © 2020. All Rights Reserved.